Trimebutine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Trimebutine: From Gastrointestinal Motility Disorders to Migraine Disorder
One-Sentence Summary
Trimebutine is an oral opioid-receptor-active gut motility modulator that is marketed in Singapore as a single-ingredient tablet. The TxGNN model predicts it may be useful for migraine disorder, but the support is limited to 0 registered clinical trials and 3 publications, only one of which is a randomized trial. The trial tested trimebutine as an add-on to a triptan, not as a stand-alone migraine treatment.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence data compiled for this report |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.64% |
| Evidence Level | L2 (one randomized, double-blind, cross-over, placebo-controlled study; no registered trials) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data were not available in the data compiled for this report. Based on known pharmacology, trimebutine is an opioid receptor agonist (mu, kappa and delta) that acts on the gut's enteric nerve plexuses and affects gut motility and ion channels. It is used for functional gastrointestinal disorders.
The link to migraine is indirect. Gastric stasis is common during migraine attacks and can delay absorption of oral acute drugs such as triptans. A motility-modulating drug might therefore speed up absorption and ease migraine-related nausea. This mechanism does not act on core migraine pathophysiology such as CGRP signalling or trigeminovascular activation. The most plausible role is an adjunct to acute therapy, not a stand-alone migraine treatment.
The model also gave high scores to related terms (migraine with brainstem aura, migraine susceptibility, headache disorder). These appear to inherit the general migraine signal and have no independent support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16776704 | 2006 | RCT | Cephalalgia | Double-blind, randomized, cross-over, placebo-controlled study of rizatriptan vs. rizatriptan plus trimebutine for acute migraine. The rationale was that gastroparesis delays oral drug absorption during attacks. |
| 19220673 | 2009 | Review | J Gastroenterol Hepatol | Review of prokinetic agents against diseases outside the GI tract, including the central nervous system. |
| 16245431 | 2005 | Case report | Pol Merkur Lekarski | A 9-year-old girl with abdominal migraine did not improve on drotaverine, mebeverine or trimebutine. This is not supportive evidence. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN02931P | DEBRIDAT TABLET 100 mg | Tablet | Not stated |
Safety Considerations
Please refer to the package insert for safety information. No drug-interaction records were found, and no knowledge-graph contraindications were identified. This is not evidence of safety, because the package insert warnings and contraindications could not be retrieved.
Conclusion and Next Steps
Decision: Hold
Rationale: The only controlled evidence is a single small trial of trimebutine combined with rizatriptan. It supports at most an adjunctive role in acute migraine and does not show a stand-alone effect. There are no registered trials, the mechanism is indirect, and safety documentation is incomplete. Other predicted indications (for example atrophoderma vermiculata, pulmonary hypertension, open-angle glaucoma and Raynaud disease) have no supporting evidence and appear to be knowledge-graph artifacts.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore regulator (HSA), plus the approved indication for the licence
- Mechanism-of-action data from DrugBank
- Full review of the 2006 cross-over trial (sample size, endpoints, effect size), and independent replication
- A confirmatory trial in the adjunctive-use setting, if the research question is pursued
- Merging the closely related migraine and headache predictions into one assessment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.